The metabolic aspects of polycystic ovary syndrome

References

• Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod.10, 2107–2111 (1995).
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab.89, 2745–2749 (2004).
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril.81, 19–25 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R. How prevalent is metabolic syndrome in women with polycystic ovary syndrome? Nat. Clin. Pract. Endocrinol. Metab.2, 132–133 (2006).
   PubMedGoogle Scholar
• Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum. Reprod.23, 2352–2358 (2008).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism52, 908–915 (2003).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91, 48–53 (2006).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am.28, 341–359 (1999).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.82, 524–530 (1997).
   PubMed Web of Science ®Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev.20, 535–582 (1999).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am. J. Physiol. Endocrinol. Metab.281, 392–399 (2001).
   PubMed Web of Science ®Google Scholar
• Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract. Res. Clin. Obstet. Gynaecol.18, 685–706 (2004).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J. Clin. Endocrinol. Metab.91, 22–24 (2006).
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet370, 685–697 (2007).
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med.8, 41 (2010).
   PubMed Web of Science ®Google Scholar
• Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J. Clin. Endocrinol. Metab.90, 6014–6021 (2005).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil. Steril.95(3), 1048–1058 (2010).
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG113, 1203–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Faloia E, Canibus P, Gatti C et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J. Endocrinol. Invest.27, 424–429 (2004).
   PubMed Web of Science ®Google Scholar
• Samaras K, Campbell LV. Increasing incidence of Type 2 diabetes in the third millennium: is abdominal fat the central issue? Diabetes Care23, 441–442 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and Type 2 diabetes. Endocr. Rev.23, 201–229 (2002).
   PubMed Web of Science ®Google Scholar
• Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW. The role of intramuscular lipid in insulin resistance. Acta Physiol. Scand.178, 373–383 (2003).
   PubMedGoogle Scholar
• Motoshima H, Wu X, Sinha MK, Hardy VE. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab.87, 5662–5667 (2002).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Henriksen JE, Andersen M et al. The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian, premenopausal women with hirsutism as primary diagnosis. Fertil. Steril.82, 1570–1579 (2004).
   PubMed Web of Science ®Google Scholar
• Moran LJ, Noakes M, Clifton PM et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J. Clin. Endocrinol. Metab.89, 3337–3344 (2004).
   PubMed Web of Science ®Google Scholar
• Osuna JA, Gómez-Pérez R, Arata-Bellabarba G, Villaroel V. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch. Androl.52, 355–361 (2006).
   PubMedGoogle Scholar
• Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol.126, 81–86 (2006).
   PubMed Web of Science ®Google Scholar
• Pugeat M, Crave JC, Elmidani M. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J. Steroid Biochem. Mol. Biol.40, 841–849 (1991).
   PubMed Web of Science ®Google Scholar
• De Pergola G, Giagulli VA, Garruti G et al. Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. Metabolism40, 187–190 (1991).
   PubMedGoogle Scholar
• Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin. Endocrinol. (Oxf.)41, 473–481 (1994).
   PubMed Web of Science ®Google Scholar
• Taponen S, Martikainen H, Järvelin MR et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J. Clin. Endocrinol. Metab.88, 141–147 (2003).
   PubMed Web of Science ®Google Scholar
• Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil. Steril.92, 643–647 (2009).
   PubMed Web of Science ®Google Scholar
• Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur. J. Endocrinol.150, 161–171 (2004).
   PubMed Web of Science ®Google Scholar
• Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J. Endocrinol.183, 331–342 (2004).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. (Oxf.)39, 1–16 (1993).
   PubMed Web of Science ®Google Scholar
• Plymate SR, Jones RE, Matej LA, Friedl KE. Regulation of sex hormone binding globulin (SHBG). Production in Hep G2 cells by insulin. Steroids52, 339–340 (1988).
   PubMedGoogle Scholar
• Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol.40(1), 189–207 (2010).
   PubMed Web of Science ®Google Scholar
• Westerveld HE, Hoogendoorn M, de Jong AW, Goverde AJ, Fauser BC, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol. Ther.119, 223–241 (2008).
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina EJ. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. Clin. Endocrinol. Metab.92, 186–189 (2007).
   Google Scholar
• Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol. Metab.18, 280–285 (2007).
   PubMed Web of Science ®Google Scholar
• Goverde AJ, van Koert AJ, Eijkemans MJ et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum. Reprod.24, 710–717 (2009).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med.23, 469–480 (2006).
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.)52, 595–600 (2000).
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Camb.)3, 101–105 (2000).
   PubMedGoogle Scholar
• Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine30, 45–53 (2006).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA287, 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1929–1935 (2005).
   PubMed Web of Science ®Google Scholar
• Legro RS. Type 2 diabetes and polycystic ovary syndrome. Fertil. Steril.86, 116–117 (2006).
   Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab.90, 3236–3242 (2005).
   PubMed Web of Science ®Google Scholar
• Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with Type 2 diabetes. Diabetes Care24, 1050–1052 (2001).
   PubMed Web of Science ®Google Scholar
• Stuart CA, Wen G, Williamson ME et al. Altered GLUT1 and GLUT3 gene expression and subcellular redistribution of GLUT4: protein in muscle from patients with acanthosis nigricans and severe insulin resistance. Metabolism50, 771–777 (2001).
   PubMedGoogle Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol.237, 214–223 (1979).
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care23, 57–63 (2000).
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab.85, 2402–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care26, 3320–3325 (2003).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Fritsche A, Häring H. The OGTT as test for β cell function? Eur. J. Clin. Invest.31, 380–381 (2001).
   PubMedGoogle Scholar
• Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. The biological variation of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab.87, 1560–1562 (2002).
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J. Clin. Endocrinol. Metab.88, 1528–1533 (2003).
   PubMed Web of Science ®Google Scholar
• NICE. Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. National Institute for Health and Clinical Excellence (2006).
   Google Scholar
• NICE. Fertility: Assessment and Treatment for People With Fertility Problems CG 11. National Institute for Health and Clinical Excellence (2004).
   Google Scholar
• Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)36, 105–111 (1992).
   PubMed Web of Science ®Google Scholar
• Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.80, 2586–2593 (1995).
   PubMed Web of Science ®Google Scholar
• Hays NP, Starling RD, Liu X et al. Effects of an ad libitum low-fat, high-carbohydrate diet on body weight, body composition, and fat distribution in older men and women: a randomized controlled trial. Arch. Intern. Med.164, 210–217 (2004).
   PubMed Web of Science ®Google Scholar
• Galletly C, Moran L, Noakes M, Clifton P, Tomlinson L, Norman R. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome – a pilot study. Appetite49, 590–593 (2007).
   PubMed Web of Science ®Google Scholar
• Clifton PM, Keogh JB, Noakes M Long-term effects of a high-protein weight-loss diet. Am. J. Clin. Nutr.87, 23–29 (2008).
   PubMed Web of Science ®Google Scholar
• Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril.81, 630–637 (2004).
   PubMed Web of Science ®Google Scholar
• Jenkins DJ. Dietary carbohydrates and their glycemic responses. JAMA251, 2829–2831 (1984).
   PubMedGoogle Scholar
• Jenkins DJ, Kendall CW, Vuksan V et al. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am. J. Clin. Nutr.75, 834–849 (2002).
   PubMed Web of Science ®Google Scholar
• Frost GS, Goff LM, Hamilton G et al. Carbohydrate-induced manipulation of insulin sensitivity independently of intramyocellular lipids. Br. J. Nutr.89, 365–375 (2003).
   PubMedGoogle Scholar
• Okay DM, Jackson PV, Marcinkiewicz M, Papino MN. Exercise and obesity. Prim. Care36, 379–393 (2009).
   PubMed Web of Science ®Google Scholar
• Palomba S, Giallauria F, Falbo A et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum. Reprod.23, 642–650 (2008).
   PubMed Web of Science ®Google Scholar
• Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol. Rev.59, 151–184 (2007).
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med.363, 905–917 (2010).
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet370, 1706–1713 (2007).
   PubMed Web of Science ®Google Scholar
• Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with Type 2 diabetes. Diabetes Care29, 2361–2364 (2006).
   PubMedGoogle Scholar
• Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA292, 1724–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Sjöström L, Narbro K, Sjöström CD et al. Swedish obese subjects study effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med.357, 741–752 (2007).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JLJ. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. Clin. Endocrinol. Metab.90, 6364–6369 (2005).
   Google Scholar
• Eid GM, Cottam DR, Velcu LM et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis.1, 77–80 (2005).
   PubMedGoogle Scholar
• Karmon A, Sheiner E. Timing of gestation after bariatric surgery: should women delay pregnancy for at least 1 postoperative year? Am. J. Perinatol.25, 331–333 (2008).
   PubMed Web of Science ®Google Scholar
• Scholtz S, Le Roux C, Balen AH. The role of bariatric surgery in the management of female fertility. Hum. Fertil. (Camb.)13, 67–71 (2010).
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev.1, CD003053 (2010).
   Google Scholar
• Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med.121, 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Yasmin E, Barth JH, Glanville J, Balen AH. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in Polycystic Ovary Syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol.156(1), 67–71 (2011).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS et al.; PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab.86, 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med.351, 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Ortega-González C, Luna S, Hernández L et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1360–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod.23, 462–477 (2008).
   PubMed Web of Science ®Google Scholar